Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study

被引:60
作者
Miners, AH [1 ]
Garau, M
Fidan, D
Fischer, AJ
机构
[1] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England
[2] Univ York, Dept Econ, York YO1 5DD, N Yorkshire, England
[3] Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England
[4] Univ London St Georges Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2005年 / 330卷 / 7482期
关键词
D O I
10.1136/bmj.38285.482350.82
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the association between different types of organisation and the results front economic evaluations. Design Retrospective pairwise comparison of evidence submitted to the technology appraisal programme of the National Institute for Clinical Excellence (NICE) by manufacturers of the relevant healtltcare technologies and by contracted university based assessment groups. Data sources Data front the first 62 appraisals. Main outcome measure Incremental cost effectiveness ratios. Results Data from 27 of the 62 appraisals could be compared. The analysis of 54 pairwise comparisons showed that manufacturer's estimates of incremental cost effectiveness ratios were lower (suggesting a snore cost effective use of resources) than those produced by the assessment groups (25 were lower, 29 were the wine, none were higher, P < 0.01). Restriction of this dataset to include only one pairwise comparison per appraisal (27 pairs) produced a similar result (21 were lower, two were the same, four were higher, P < 0.001). Conclusions The estimated incremental cost effectiveness ratios submitted by manufacturers were on average significantly lower than those submitted by the assessment groups. These results show that an important role of NICE's appraisal committee, and of decision makers in general, is to determine which economic evaluations, or parts of evaluations, should be given more credence.
引用
收藏
页码:65 / 68
页数:8
相关论文
共 13 条
[1]   Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events? [J].
Als-Nielsen, B ;
Chen, WD ;
Gluud, C ;
Kjaergard, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :921-928
[2]   The effectiveness of cost-effectiveness analysis in containing costs [J].
Azimi, NA ;
Welch, HG .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1998, 13 (10) :664-669
[3]   Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease [J].
Briggs, AH ;
Goeree, R ;
Blackhouse, G ;
O'Brien, BJ .
MEDICAL DECISION MAKING, 2002, 22 (04) :290-308
[4]   Handling uncertainty in cost-effectiveness models [J].
Briggs, AH .
PHARMACOECONOMICS, 2000, 17 (05) :479-500
[5]   Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis [J].
Devlin, N ;
Parkin, D .
HEALTH ECONOMICS, 2004, 13 (05) :437-452
[6]  
Drummond M., 2015, METHODS EC EVALUATIO, V4
[7]   Evaluation of conflict of interest in economic analyses of new drugs used in oncology [J].
Friedberg, M ;
Saffran, B ;
Stinson, TJ ;
Nelson, W ;
Bennett, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15) :1453-1457
[8]   The ISPOR good practice modeling principles - A sensible approach: Be transparent, be reasonable [J].
Garrison, LP .
VALUE IN HEALTH, 2003, 6 (01) :6-8
[9]  
Gold MR, 1996, COST EFFECTIVENESS H
[10]   Pharmaceutical industry sponsorship and research outcome and quality: systematic review [J].
Lexchin, J ;
Bero, LA ;
Djulbegovic, B ;
Clark, O .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7400) :1167-1170B